Fig. 4
From: Neutralizing antibody responses to three XBB protein vaccines in older adults
Neutralizing antibody responses in individuals with or without medical conditions before and after immunization with three XBB-containing vaccines. a–d Comparison of the 50% neutralization titer (NT50) against the indicated pseudoviruses in individuals with (n = 13) and without (n = 17) medical conditions before receiving the trivalent XBB.1.5 booster (a), in individuals with (n = 20) and without (n = 10) medical conditions before receiving the bivalent Omicron XBB vaccine (b), in individuals with (n = 11) and without (n = 19) medical conditions before receiving the tetravalent XBB.1 vaccine (c), and in all pooled sera (d). e–h NT50 of individuals with and without medical conditions after immunization with the trivalent XBB.1.5 booster (e), bivalent Omicron XBB vaccine (f), tetravalent XBB.1 vaccine (g), or all pooled sera after immunization (h). Each dot represents the NT50 for an individual. The horizontal dotted line in the neutralization assay reflects a limit of detection of 30, with serum samples exhibiting neutralization below 30 represented as 10. The bar represents the GMTs and 95% confidence intervals. Statistical analyses were performed using the Wilcoxon rank-sum test for group comparisons of GMTs between individuals with and without chronic conditions. A p-value <0.05 was considered statistically significant, and only significant differences are displayed in the figure
